New Zealand-based Innate Immunotherapeutic would now be going ahead with next stage of its clinical trials in Australia. The company made this announcement in wake of the success of its earlier tests of MIS416 in patients that are suffering from chronic progressive multiple sclerosis (MS).
According to the Chief Executive Officer of Innate Immunotherapeutic, Simon Wilkinson, "We are very encouraged in the potential of MIS416 as a treatment for secondary progressive MS based on the results from this trial to date". He went on to add that their next stage of clinical test would be aimed to investigate the sustainability of the improvements of the drug that were obtained in the phase I/II. The third phase of the study tagged IIB would continue for a period of one year.
The company decided to go in for the testing of the drugs, after last year, the government of Australia gave a 45% tax incentive on the R&D to the company. This is a big boost for the company whose main focus has been to develop immune modifier drug in the treatment of various disease that include Multiple Sclerosis, certain cancers and humoral adjuvant. Currently, MIS416 is the main product from Innate Immunotherapeutic that has made possible due to the immune modulating microparticle technology.